CAPO: Continuous Glucose Monitoring in A2 Gestational Diabetes and Pregnancy Outcomes (NCT04219085) | Clinical Trial Compass
CompletedNot Applicable
CAPO: Continuous Glucose Monitoring in A2 Gestational Diabetes and Pregnancy Outcomes
United States65 participantsStarted 2020-09-01
Plain-language summary
This study will utilize continuous glucose monitoring in women with A2 gestational diabetes. Women will be randomized to continuous glucose monitoring or routine care with fingersticks to check their blood glucose four times daily. It is hypothesized that women in the continuous glucose monitoring arm will have a lower incidence of the composite primary outcome, which includes the following variables: perinatal death, shoulder dystocia, birth weight greater than 4,000 grams, NICU admission for treatment of hypoglycemia (blood glucose level \<40mg/dL) and birth trauma, including fracture or nerve palsy.
Who can participate
Age range18 Years – 50 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* women between 18-50 years old
* pregnant
* singleton gestation
* diagnosis of gestational diabetes requiring medication (A2) during the current pregnancy between 24-36 weeks' gestation
Exclusion Criteria:
* pregestational diabetes
* diagnosis with gestational diabetes \< 24 weeks gestation or \> 36 weeks gestation
* known fetal anomalies
* fetal growth restriction diagnosed during the current pregnancy
* diagnosis of polyhydramnios at time of randomization
* abnormal diagnostic genetic testing or genetic screening for the fetus in the current pregnancy prior to randomization
* twin or higher order multiple gestation
* non-compliance with prenatal visits (missing ≥3 visits prior to enrollment) prior to diagnosis with A2 gestational diabetes
* maternal medical comorbidities including the following: lupus, chronic hypertension, cancer, ischemic cardiovascular disease
What they're measuring
1
Composite Primary Outcome
Timeframe: from enrollment up until delivery by 41 weeks gestation, up to 19 weeks total